Sugi Predict

Sugi Predict / Compounds / SCHEMBL14768656

SCHEMBL14768656

SCHEMBL14768656

Cc1cc(Cl)cc(Sc2ccc([N+](=O)[O-])cc2CN2CCS(=O)(=O)CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ ACHE P22303 2/20 0.41
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ PDE7A Q13946 3/20 0.39
▸ L3MBTL1 Q9Y468 3/20 0.39
▸ MAPT P10636 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ CTSB P07858 1/20 0.38
▸ CDK1 P06493 1/20 0.38
▸ CCNB1 P14635 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ PDE7B Q9NP56 1/20 0.38
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14768636 0.87 LMNA (0.59) LMNASMN1; SMN2KDM4EALDH1A1ACHE
SCHEMBL15334544 0.82 PDE7A (0.40) LMNASMN1; SMN2ALDH1A1KMT2APDE7A
SCHEMBL13099398 0.82 ALDH1A1 (0.46) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL14768622 0.81 KMT2A (0.40) ALDH1A1MEN1KMT2A
SCHEMBL14768587 0.79 LMNA (0.59) LMNASMN1; SMN2KDM4EALDH1A1ACHE
SCHEMBL13157394 0.73 ALDH1A1 (0.50) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL14768599 0.73 KMT2A (0.41) SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL15334543 0.71 LMNA (0.41) LMNASMN1; SMN2KDM4EALDH1A1PDE7A
SCHEMBL19720320 0.71 ALDH1A1 (0.47) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL14768607 0.68 CHRNA7 (0.39) SMN1; SMN2ALDH1A1L3MBTL1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160031841-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. 2016-02-04 — — US disclosed
US-9187425-B2 2,5-disubstituted arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2015-11-17 — — US disclosed
US-20140066446-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2014-03-06 — — US disclosed
US-8563544-B2 2,5-disubstituted arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2013-10-22 — — US disclosed
US-20130065889-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2013-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031841-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 LMNA 4120/4885SMN1; SMN2 603/4885KDM4E 2880/4885
US-20140066446-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 LMNA 4120/4885SMN1; SMN2 603/4885KDM4E 2880/4885
US-20130065889-A1 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 LMNA 4120/4885SMN1; SMN2 603/4885KDM4E 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.